Who owns Pieris Pharmaceuticals?
- Ticker: PIRS
- CUSIP Number: 720795103
Tip: Access positions for across all investors
Analyze quarterly positions in Pieris Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Pieris Pharmaceuticals stock
Who bought or sold Pieris Pharmaceuticals this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
BVF | 21M | $3.8M | 0% | Mar 2024 |
|
Lynx1 Capital Management | 8.8M | $1.6M | -10% | Mar 2024 |
|
BlackRock | 1.0M | $190k | 0% | Mar 2024 |
|
Citadel Advisors | 967k | $179k | -23% | Mar 2024 |
|
Acadian Asset Management | 962k | $175k | 0% | Mar 2024 |
|
Vanguard Group | 907k | $166k | 0% | Mar 2024 |
|
Geode Capital Management | 773k | $142k | 1% | Mar 2024 |
|
CM Management | 575k | $105k | -23% | Mar 2024 |
|
Northern Trust | 244k | $45k | 77% | Mar 2024 |
|
Millennium Management | 212k | $39k | 27% | Mar 2024 |
|
Squarepoint Ops | 146k | $27k | 100% | Mar 2024 |
|
Summit Trail Advisors | 140k | $26k | 100% | Mar 2024 |
|
Citigroup | 89k | $16k | 0% | Mar 2024 |
|
Two Sigma Securities | 58k | $11k | 278% | Mar 2024 |
|
UBS Group | 52k | $9.5k | 728% | Mar 2024 |
|
Tower Research Capital | 43k | $7.8k | 38% | Mar 2024 |
|
Two Sigma Advisers | 34k | $6.2k | -2% | Mar 2024 |
|
Raymond James & Associates | 30k | $5.5k | 0% | Mar 2024 |
|
NJ State Employees Deferred Compensation Plan | 30k | $5.5k | 0% | Mar 2024 |
|
Group One Trading | 26k | $4.7k | 282% | Mar 2024 |
|
Goldman Sachs Group | 23k | $332k | 0% | Mar 2024 |
|
XTX Topco | 21k | $3.8k | 100% | Mar 2024 |
|
Commerce Bank N A | 20k | $3.7k | 0% | Mar 2024 |
|
Kestra Advisory Services | 18k | $3.2k | 100% | Dec 2023 |
|
National Asset Management | 17k | $5.1k | 100% | Mar 2024 |
|
Hudson Valley Investment Advisors | 14k | $2.6k | 0% | Mar 2024 |
|
HPM Partners | 10k | $1.9k | 0% | Mar 2024 |
|
Us Bancorp | 10k | $1.9k | 0% | Mar 2024 |
|
Morgan Stanley | 6.9k | $1.3k | -16% | Mar 2024 |
|
Bank of America Corporation | 6.1k | $1.1k | 4138% | Mar 2024 |
|
Wells Fargo & Company | 5.6k | $1.0k | 17% | Mar 2024 |
|
Barclays | 5.0k | $1.0k | 0% | Mar 2024 |
|
Cutler | 4.5k | $0 | 0% | Mar 2024 |
|
Jpmorgan Chase & Co | 2.0k | $364.583700 | 1% | Mar 2024 |
|
Advisor Group Holdings | 516.00 | $94.995600 | 0% | Mar 2024 |
|
Hanson McClain Advisors | 350.00 | $64.995000 | 0% | Mar 2024 |
|
Royal Bank of Canada | 272.00 | $0 | -52% | Mar 2024 |
|
Who sold out of Pieris Pharmaceuticals?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Virtu Financial | Dec 2023 | 90k | $16k |
Two Sigma Investments | Dec 2023 | 41k | $7.4k |
Bank of New York Mellon | Dec 2023 | 40k | $7.3k |
NorthStar Asset Management | Dec 2023 | 39k | $7.1k |
Baader Bank | Dec 2023 | 20k | $2.7k |
1620 Investment Advisors | Dec 2023 | 4.4k | $318k |
Rhumbline Advisers | Dec 2023 | 1.9k | $339.052200 |